All posts related to "Report Card"

Le Réseau canadien en obésité publie le premier bilan du genre au Canada

Le Réseau canadien en obésité publie le premier bilan du genre au Canada : Bulletin 2017 sur l’accès des adultes au traitement de l’obésité au Canada

Une modification de paradigme dans la prévention et le traitement de l’obésité.

Report Card on Obesity Treatment Cover PhotoLe bulletin semble prêt à passer du concept qui attribuait l’obésité à de simples mauvais choix de mode de vie pour évoluer vers celui du modèle socio-écologique de santé comportant l’obligation, pour nos systèmes de santé comme pour la société, de prévenir et de traiter l’obésité au même titre que d’autres maladies chroniques.

Comprendre votre indice de masse corporelle (IMC)
Le document Lignes directrices pour la classification du poids chez les adultes, publié par Santé Canada, s’appuie sur l’indice de masse corporelle (IMC) pour déterminer si une personne souffre d’un excès de poids. Vous pouvez calculer votre IMC en ligne ici ou en utilisant la formule suivante :

IMC = poids (kg) / taille (m)2

Le tableau Classification du risque pour la santé en fonction de l’indice de masse corporelle (IMC) publié par Santé Canada montre la corrélation entre l’IMC et le risque de développer certains problèmes de santé tels que le diabète de type 2, l’hypertension, une maladie coronarienne, un accident vasculaire cérébral et le cancer. D’autres facteurs peuvent influer sur votre IMC. Il est recommandé de consulter votre médecin de famille si votre excès de poids devient une préoccupation pour vous.
Continue reading

Canadian Obesity Network publishes first-ever Report Card On Access to Obesity Treatment

Canadian Obesity Network publishes first-ever Report Card On Access to Obesity Treatment For Adults in Canada 2017

A paradigm shift in the prevention and treatment of obesity.

Report Card on Obesity Treatment Cover PhotoThe report is a shift away from considering obesity to be merely the result of poor lifestyle choices toward a socio-ecological model of health that carries with it an obligation to our health systems and society to prevent and treat it as we do other chronic diseases.

Understanding your Body Mass Index (BMI)
Health Canada’s Canadian Guidelines for Body Weight Classification in Adults uses the Body Mass Index (BMI) to determine if someone is overweight. You can calculate your BMI using the formula below or online here:

BMI = weight (kg)/height (m)2

Health Canada’s Health Risk Classification According to Body Mass Index (BMI) table shows the correlation between your BMI score and your risk of developing health problems, such as type 2 diabetes, high blood pressure, heart disease, stroke, arthritis and cancer. Please note other factors may influence your BMI. You should consult your family physician if you are concerned about being overweight.
Continue reading

The lastest provincial listings, at your fingertips

Map of Canada

(Please click on the map for more information about the provincial drug formulary updates.)

The latest provincial listings, at your fingertips

Good news for people living with autoimmune arthritis in Canada!

Arthritis Consumer Experts (ACE) maps out the latest news for you: Read about the important changes to provincial drug formularies and what it means for Canadians living with autoimmune arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA). Continue reading

ACE Releases 9th Annual Arthritis Medications Report Card

Report Card Slide BannerGood news/bad news for Canadians living with arthritis, depending on where they live

Arthritis Consumer Experts (ACE) has released its Ninth Annual JointHealth™ Arthritis Medications Report Card with a clear message to the federal and provincial governments in Canada: Reimbursement access to arthritis medications has improved in many Canadian provinces, however, disappointing inequities remain in patient/physician choice and patient access to reimbursement for the medication prescribed for them by their rheumatologist.

“Thanks to the advocacy efforts of people living with arthritis and their rheumatologists, progress has been made in many Canadian provinces. We encourage the federal and provincial governments to maintain their commitment to the estimated 600,000 Canadians living with a type of autoimmune arthritis – rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis – and their right to choose with their healthcare team the therapy best suited to their disease biology, which is distinctly different from patient to patient,” said Cheryl Koehn, Founder and President, Arthritis Consumer Experts. Continue reading

JointHealth™ monthly – December 2015: The Report Card

The JointHealth™ Arthritis Medications Report Card

How does your province compare?
Picture of Report Card

 

During the last year, Arthritis Consumer Experts continuously monitored scientific and medication treatment advances that have the potential to affect the lives of those living with arthritis. The JointHealth™ Arthritis Medications Report Card summarizes and ranks these medication treatment advances and helps Canadians and their rheumatologists identify how their province measures up to other provinces in terms of providing reimbursement access to medications approved for autoimmune forms of arthritis.

The understanding of combination medication therapy allows people with arthritis to live healthier, more productive lives. To help prepare the arthritis consumer with the information they need to talk to their healthcare provider, this issue of JointHealth™monthly will also look at:

  • New arthritis medications on the horizon
  • The coast-to-coast discussion about a national pharmacare program
  • Take action now to improve your province’s drug formulary ranking

What can patients like you do? Continue reading

Good news in Quebec!

Good news in Quebec!

Tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis approved in Quebec.

Approved stampAs of June 1st, tofacitinib (Xeljanz®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on Quebec’s drug formulary. Click here to view the detailed medication criteria.

Tofacitinib is an oral targeted small molecule medicine (TSMM) that was issued a Notice of Compliance (NOC) from Health Canada on April 17, 2014. Tofacitinib in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of RA, in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of tofacitinib as monotherapy.

Click here to view the most up-to-date version of ACE’s Report Card on provincial formulary reimbursement listings for biologic response modifiers.